<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137949">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02018081</url>
  </required_header>
  <id_info>
    <org_study_id>10 150 02</org_study_id>
    <nct_id>NCT02018081</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Levofloxacin in Intensive Care Unit</brief_title>
  <acronym>LEVO-PHARM</acronym>
  <official_title>Population Pharmacokinetics of Levofloxacin in Intensive Care Patients With Severe Community-acquired Pneumonia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is 1. to describe levofloxacin pharmacokinetics in ICU patients
      suffering from pneumonia with taking into account physio-pathological parameters. 2. to
      verify clinical and bacteriological efficiency and to know if the peak/Minimum Inhibitory
      Concentration (MIC) ratio &gt; 5 and Area Under Curve (AUC) /Minimum Inhibitory
      Concentration(MIC) ratio &gt; 125. No therapeutic drug monitoring will be performed in this
      study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Levofloxacin dosage regimen, time of administration and time of blood sampling, levofloxacin serum concentrations.</measure>
    <time_frame>Levofloxacin concentration assessment at  8 different  time points during 12h</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficiency (clinical,bacteriological, pharmacodynamic)</measure>
    <time_frame>12 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>age, weight, height, sex, SAPS II, blood urea nitrogen (BUN), creatinine, mechanical ventilation, leukocytes, haemoglobin, procalcitonin, creatinine clearance, proteins, MIC of the strain.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Intensive Care Unit Syndrome</condition>
  <condition>Community-acquired Pneumonia</condition>
  <arm_group>
    <arm_group_label>Levofloxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Population having a community-acquired pneumonia of wich the indication of the treatment is administration of Levofloxacin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin</intervention_name>
    <description>8 blood sampling by patients between the 48th and 60th</description>
    <arm_group_label>Levofloxacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  severe community-acquired pneumonia due to a strain sensible to levofloxacin

          -  Age &gt; 18 years

          -  Informed consent

          -  SAPS II (simplified acute physiological score) &gt; 20 Awaited duration of survival
             higher than 7 days

        Exclusion Criteria:

          -  Historic of allergy to levofloxacin

          -  Resistant strain to levofloxacin

          -  Pregnancy

          -  Contra-indications of levofloxacin use, renal failure
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard GEORGES, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bernard GEORGES, MD, PhD</last_name>
    <phone>05 61 32 23 41</phone>
    <phone_ext>33</phone_ext>
    <email>georges.b@chu-toulouse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Marie CONIL, MD, PhD</last_name>
    <phone>05 61 32 24 86</phone>
    <phone_ext>33</phone_ext>
    <email>conil.jm@chu-toulouse.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard GEORGES, MD, PhD</last_name>
      <phone>05 61 32 23 41</phone>
      <phone_ext>33</phone_ext>
      <email>georges.b@chu-toulouse.fr</email>
    </contact>
    <contact_backup>
      <last_name>Jean-Marie CONIL, MD, PhD</last_name>
      <phone>05 61 32 24 86</phone>
      <phone_ext>33</phone_ext>
      <email>conil.jm@chu-toulouse.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Michèle GENESTAL, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Béatrice RIU, Md, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre COUGOT, Md, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphanie RUIZ, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-François DECUN, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 16, 2013</lastchanged_date>
  <firstreceived_date>July 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetic study : open, prospective, monocentric</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ofloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
